NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Jan 2004
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
18
Mechanism of Action
Reduction Activity
Pharmacologic Class:
Antidote
Clinical Trials (5)
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
Started Sep 2024
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
Started Jul 2023
18 enrolled
Mitochondrial Disease
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
Started Dec 2020
58 enrolled
Neurofibromatosis 1
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
Started Sep 2020
165 enrolled
COVIDSars-CoV2SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere+1 more
N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI
Started Aug 2016
30 enrolled
Traumatic Brain Injury (TBI)Hazardous and Harmful Alcohol Use
Loss of Exclusivity
LOE Date
Apr 6, 2032
74 months away
Patent Expiry
Apr 6, 2032
Exclusivity Expiry
Nov 26, 2027